Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

• Status: Completed
• Trial end date: 2021-04-15
• Target enrollment: 0
• Participant gender: All

Summary

This study is aimed at assessing the efficacy of Apraclonidine eye drops in the treatment of ptosis secondary to myasthenia gravis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: American University of Beirut Medical Center
• Treatments: Apraclonidine

Criteria

Inclusion Criteria:

• Patients aged 18 or older with a diagnosis of ocular or generalized myasthenia gravis with ocular involvement.

Exclusion Criteria:

• Patients receiving mono-amino-oxidase inhibitors.

• Patients with history of hypertension, cardiac, or cerebrovascular disease.

• Women with confirmed pregnancy.